
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026**

Revvity, Inc.
(Exact Name of Registrant as Specified in its Charter)

Massachusetts
(State or Other Jurisdiction
of Incorporation or Organization)

001-05075
(Commission
File Number)

04-2052042
(IRS Employer
Identification No.)

77 4th Avenue,

Waltham,
(Address of Principal Executive Offices)

Massachusetts

02451
(Zip Code)

Registrant's telephone number, including area code: (781) 663-6900

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, \$1 par value per share 1.875% Notes due 2026	RVTY RVTY 26	The New York Stock Exchange The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition

On January 12, 2026, Revvity, Inc. (the “Company”) announced preliminary expectations with respect to certain financial results for the fourth quarter ended December 28, 2025 and announced that the Company will release its fourth quarter and full year 2025 financial results on February 2, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01. Regulation FD Disclosure

On January 13, 2026, Dr. Prahlad Singh, President and Chief Executive Officer of the Company, is scheduled to make a presentation to the 44th Annual J. P. Morgan Healthcare Conference. A copy of the presentation materials is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

EXHIBIT INDEX

Exhibit No.	Description
99.1*	Press Release entitled “Revvity to Hold Earnings Call on Monday, February 2, 2026: Provides Update on Financial Performance”, issued by Revvity, Inc. on January 12, 2026
99.2*	Revvity, Inc. Presentation to the 44th Annual J.P. Morgan Healthcare Conference, January 13, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL)

* This exhibit relating to Item 2.02 and 7.01 shall be deemed to be furnished, and not filed..

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2025

REVVITY, INC.
By: /s/ Maxwell Krakowiak
Maxwell Krakowiak
Senior Vice President and Chief Financial Officer

Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

WALTHAM, Mass. - January 12, 2026 – Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

To access the call, a live audio webcast will be available on the Investors section of the Company's website.

Update on Financial Performance

The Company is also providing the following preliminary financial results for the fourth quarter 2025:

- Reported and organic revenue growth for the fourth quarter is expected to be approximately 6% and 4%, respectively, as compared to the same period a year ago. This is expected to result in fourth quarter revenue of approximately \$772 million. For the full year 2025, reported and organic revenue growth is expected to be approximately 4% and 3%, respectively, as compared to the same period a year ago. This is expected to result in full year 2025 revenue of approximately \$2,855 million.
- The Company also now expects its full year adjusted earnings per share to exceed the upper-end of the \$4.90-\$5.00 guidance provided on October 27, 2025.

J.P. Morgan Healthcare Conference

As previously announced, Prahlad Singh, will present at 9:45 a.m. PT tomorrow (January 13, 2026) at the 44th annual J.P. Morgan Healthcare Conference. A live audio webcast of the presentation will be available via this page. A copy of the accompanying slide presentation will be made available on the Investors section of the Company's website.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below under Explanation of Non-GAAP Financial Measures.

Full year 2025 adjusted earnings per share guidance is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future adjusted earnings per share, revenue, revenue growth and other financial results. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations

and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: the completion of quarterly and year end closing procedures for the fourth quarter and fiscal year ended December 28, 2025 and other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than \$2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

Continuing Operations	
Three Months Ended	
<u>December 28, 2025</u>	
<i>Projected</i>	
	6%
	2%
	0%
	4%

Organic revenue growth:

Reported revenue growth from continuing operations
Less: effect of foreign exchange rates
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses
Organic revenue growth from continuing operations

Continuing Operations	
Twelve Months Ended	
<u>December 28, 2025</u>	
<i>Projected</i>	
	4%
	1%
	0%
	3%

(1) amounts may not sum due to rounding

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to

make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” or “organic growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

Investor Relations:

Steve Willoughby
steve.willoughby@revvity.com

Media Relations:

Chet Murray
(781) 462-5126
chet.murray@revvity.com



revvity

**J.P. Morgan
44th Healthcare
Conference**

Prahlad Singh
Chief Executive Officer
January 13, 2026



Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to the Company's customers and end-markets, plans concerning business development opportunities, and acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that the Company's assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in the Company's most recent quarterly report on Form 10-Q and in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also includes non-GAAP financial measures. Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The amounts and timing of such events and items could be material to the Company's results prepared in accordance with GAAP.

Financial Disclosures

revvity

Estimated future results and historical growth rates presented and discussed today are based on 2025 guidance as provided on October 27, 2025 (2025E)


Key Definitions:

- LSD = 1-3%
- MSD = 4-6%
- HSD = 7-9%
- LDD = 10-12%
- LRP = Long-range plan

We have undergone a meaningful transformation

Legacy




Today



revvity

Revvity at-a-glance


2025E Revenue: ~\$2.8B



 Powered by ~11,000 employees collaborating to pioneer groundbreaking solutions

Life Sciences at-a-glance


Reagents, instruments, and software offerings enabling all stages of R&D



Highly innovative reagents and instrumentation | Comprehensive SaaS solutions supporting research informatics and clinical analytics workflows | Pursuing adjacent opportunities for additional growth

Diagnostics at-a-glance


Comprehensive solutions in specialized clinical markets



High-growth specialty diagnostics portfolio | Robust offerings for screening, diagnosing and informing treatments | Driving innovation and expanding global capabilities

Bridging the gap from discovery to cure

A key player in high-value areas of the drug development lifecycle



Focusing on specialized areas requiring innovation and connecting our unique capabilities to meet customer needs

Delivering on key growth, operational and financial priorities



Capitalizing on the potential of **AI**



Expanding **scientific** and **market** reach



Strengthening **operationally** and **financially** for the future

Unlocking new frontiers with AI

Select examples:

Customer-facing

Launched

Transcribe AI

for clinical laboratory customers
→ especially valuable for screening labs which process hundreds of handwritten DBS test cards daily

~40% improvement in **workflow speed** from the reduction of manual data entry tasks

Internal

Deployed

revvityAI

for our ~11,000 employees

~10% reduction in software **development timelines**

revvity

Partnering to Deliver AI

TuneLab™ leveraging Signals Xynthetica™

Lilly + revvity signals


Building the leading marketplace for trusted, high-quality AI models

Transforming the industry by powering AI-driven discovery

Further detail on following page...

Creating a scalable, federated framework to accelerate AI-enabled drug discovery

Lilly TuneLab™ models accessible through Signals Xynthetica™, our new AI Models-as-a-Service (MaaS) framework



Eli Lilly & Revvity will initially co-fund access to Signals One™ & Xynthetica™ for biotech customers

Advancing our stated strategic priorities

Select examples:

GMP Reagents Expansion

Recent GMP investments to build:

- manufacturing capacity
- regulatory capabilities
- bioprocessing catalog offerings

In the last 12 months:
~2.5x increase in GMP bioprocessing projects
 with multiple entering the clinic

Driving downstream expansion with customers

US Immunodiagnostics Penetration

Americas revenue as % of total IDx revenue:



Increasing automation and introducing novel assays

Strategic Partnerships



Providing DNA extraction and sequencing to screen newborns for rare genetic conditions



Combining our strengths in genomic and autoimmune Dx with Sanofi's leadership in T1D therapeutics

Meaningful growth opportunities, incremental to underlying LRP

Further detail on following page...

Partnering for disease prediction and prevention

Capitalizing on opportunities in rare disease while expanding into common disease

Internally developed T1D test

Our internal capabilities:

- ✓ Autoantibody assay for neonatal detection
- ✓ Genetic risk screening
- ✓ Companion diagnostics and future therapies



Developed DBS card assay for 4 biomarkers

Advancing early detection of T1D globally

With **sanofi**

Developing and clinically validating 4-plex IVD assay and expanding access for existing RUO assay


In parallel:

Supporting Italy's mandate to identify asymptomatic early pediatric T1D cases with our new IVDR screening assay



Driving operational and financial improvements

Select examples:



revvity

Operational Excellence

- Headcount rationalization
- Supply chain optimization
- Footprint consolidation

On track to achieve 28.0% adj. operating margins in 2026

Further detail on following page...

Meaningful operational efficiency initiatives

Select examples since becoming Revvity:



Headcount rationalization

Increasing **productivity** through:

- commercial synergies
- operational integrations
- management de-layering



~10% overall headcount reduction



Supply chain optimization

Driving **materials** savings by:

- insourcing
- re-engineering
- consolidations

Improving **logistics** through:

- vendor optimization
- packaging
- strategic partnerships



Footprint consolidation

30+ rooftops impacted by downsizing, co-location, and site closure activities



By 2027, optimized footprint will deliver **~20% annual cost reductions** and **~10% footprint reduction**



2026 considerations

Assumptions:

Market Environment

Expect existing end market trends to continue into 2026

Adj. Operating Margins

On track to achieve **28.0%**

Below the Line Considerations


Increased net interest expense offset by lower share count

~18% adj. tax rate

2-3%
organic growth expected to result in **HSD adj. EPS growth**

Driving sustained, superior growth...

Reiterating our long-term growth algorithm




6-8%
LRP organic growth

200bps above market in normal market conditions

Additional upside provided by technology & licensing and Omics partnerships

...and achieving top-tier margins...



...while delivering DD adj. EPS growth

over the long term, with capital deployment providing additional upside



Bringing it all together

A Category of One



An innovative Life Sciences and Diagnostics company with a unique portfolio and leading positions in high-growth end-markets



Well-positioned with high recurring revenue along with compelling growth opportunities and resilient returns



A strategic partner to customers bridging the gap from pre-clinical to clinical stages



A company with a **transformed** portfolio that is **execution** focused



A differentiated financial profile with attractive margin expansion potential and capital deployment opportunities

revvity

revvity
